Crossmark

PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer

Crossref DOI link: https://doi.org/10.1186/s40425-019-0696-8

Published Online: 2019-08-27

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, Zi-Qi

Zhao, Jing-Jing

Pan, Qiu-Zhong

Chen, Chang-Long

Liu, Yuan

Tang, Yan

Zhu, Qian

Weng, De-Sheng

Xia, Jian-Chuan
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81572865)

National Natural Science Foundation of China (81402560)

National Natural Science Foundation of China (81472387)

Guangdong Science and Technology Department (2017A020215029)

Guangdong Science and Technology Department (2014A020212584)
License Information

Text and Data Mining valid from 2019-08-27
More Information

Article History

Received: 14 October 2018

Accepted: 30 July 2019

First Online: 27 August 2019

Ethics approval and consent to participate

: The study was approved by the Institutional Ethics Committee of the Sun Yat-sen University Cancer Center, and consent for participation and publication was obtained from all the patients included in the study and is available for review at any time.

: Not applicable.

: The authors declare that they have no competing interests.